ZA200205148B - Substances for use in treating psoriasis. - Google Patents

Substances for use in treating psoriasis. Download PDF

Info

Publication number
ZA200205148B
ZA200205148B ZA200205148A ZA200205148A ZA200205148B ZA 200205148 B ZA200205148 B ZA 200205148B ZA 200205148 A ZA200205148 A ZA 200205148A ZA 200205148 A ZA200205148 A ZA 200205148A ZA 200205148 B ZA200205148 B ZA 200205148B
Authority
ZA
South Africa
Prior art keywords
psoriasis
diacerein
treatment
pharmaceutical composition
arthritis
Prior art date
Application number
ZA200205148A
Other languages
English (en)
Inventor
Guido Di Napoli
Original Assignee
Medidom Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medidom Lab filed Critical Medidom Lab
Publication of ZA200205148B publication Critical patent/ZA200205148B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200205148A 2000-01-12 2002-06-26 Substances for use in treating psoriasis. ZA200205148B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH532000 2000-01-12

Publications (1)

Publication Number Publication Date
ZA200205148B true ZA200205148B (en) 2003-06-26

Family

ID=4291590

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200205148A ZA200205148B (en) 2000-01-12 2002-06-26 Substances for use in treating psoriasis.

Country Status (22)

Country Link
US (2) US6844365B2 (de)
EP (1) EP1248608B1 (de)
JP (1) JP4912554B2 (de)
CN (1) CN1187045C (de)
AR (1) AR026801A1 (de)
AT (1) ATE254913T1 (de)
AU (1) AU776324B2 (de)
BR (2) BRPI0107493B8 (de)
CA (1) CA2396111C (de)
CZ (1) CZ301129B6 (de)
DE (1) DE60101309T2 (de)
DK (1) DK1248608T3 (de)
ES (1) ES2210120T3 (de)
IL (2) IL150390A0 (de)
MX (1) MXPA02006610A (de)
PL (1) PL212010B1 (de)
PT (1) PT1248608E (de)
RU (1) RU2266740C2 (de)
SK (1) SK286589B6 (de)
TR (1) TR200400228T4 (de)
WO (1) WO2001051044A2 (de)
ZA (1) ZA200205148B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020128317A1 (en) * 2001-01-23 2002-09-12 Laboratories Negma Treatment of pathological conditions characterized by an increased IL-1 level
CN1321636C (zh) * 2002-12-30 2007-06-20 北京大学第一医院 大黄酸在抑制血管生成中的应用
KR101465456B1 (ko) 2005-05-16 2014-11-27 애브비 바이오테크놀로지 리미티드 미란성 다발관절염의 치료를 위한 ｔｎｆ 억제제의 용도
EP2666472A3 (de) * 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Anwendungen und Zusammensetzungen zur Behandlung von Psoriasis-Arthritis
US20080085912A1 (en) * 2006-10-06 2008-04-10 Unitech Pharmaceuticals, Inc. Isoxazole derivatives and methods of treating diseases
EP2060562A1 (de) * 2007-11-16 2009-05-20 Laboratoire Medidom S.A. Dioxoanthracen-Sulfonat-Derivate
WO2009133430A1 (en) * 2008-04-30 2009-11-05 Wockhardt Research Centre Topical compositions of rhein or diacerein
CN101537002B (zh) * 2009-04-24 2012-02-29 安士制药（中山）有限公司 具有优良溶出性能的双醋瑞因组合物及其制备和用途
EP2555618B1 (de) * 2010-04-08 2015-12-30 TWI Biotechnology, Inc. Verfahren zur verwendung von diacerein als unterstützungstherapie für diabetes
WO2017123672A1 (en) * 2016-01-12 2017-07-20 Lawrence Chan Combination treatment for inflammatory diseases
CN106236729A (zh) * 2016-07-31 2016-12-21 合肥远志医药科技开发有限公司 一种双醋瑞因胶囊制剂及其制备方法
CN106692109A (zh) * 2017-01-02 2017-05-24 佛山市腾瑞医药科技有限公司 一种微孔膜控释包衣双醋瑞因微丸及其制备方法
US10675260B2 (en) * 2017-01-19 2020-06-09 Twi Biotechnology, Inc. Methods and pharmaceutical compositions for preventing or treating immunoinflammatory dermal disorders
CN106667954A (zh) * 2017-02-14 2017-05-17 佛山市腾瑞医药科技有限公司 一种双醋瑞因软胶囊制剂及其制备工艺
CN106619555A (zh) * 2017-02-14 2017-05-10 佛山市腾瑞医药科技有限公司 一种双醋瑞因速释微丸制剂、制备方法
CN106727360A (zh) * 2017-02-16 2017-05-31 佛山市腾瑞医药科技有限公司 一种双醋瑞因固体分散体制剂及其制备方法
WO2019186561A1 (en) * 2018-03-29 2019-10-03 S.I.S Shulov Innovative Science Ltd. Pharmaceutical compositions for inhibiting inflammatory cytokines
WO2021011538A1 (en) * 2019-07-15 2021-01-21 R.P. Scherer Technologies, Llc Capsule dosage forms, methods of preparation and methods of use thereof
CN112755013A (zh) * 2021-02-22 2021-05-07 北京市中医研究所 大黄酸作为s100a8的抑制剂在炎症性疾病中的制药应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA761627B (en) 1976-03-16 1978-01-25 C Friedmann Improvements in or relating to the treatment of arthritis
IT1197316B (it) * 1986-10-01 1988-11-30 Proter Spa Formulazione galenica ad uso orale di derivati della reina a lento rilascio per impiego terapeutico
IT1264545B1 (it) 1993-07-30 1996-10-02 Medidom Lab Procedimento per la preparazione della diacereina
IT1282381B1 (it) 1996-04-29 1998-03-20 Trans Bussan S A Nuove formulazioni di diacereina, ottenute per inclusione del principio attivo in idrogel polisaccaridi
IT1283772B1 (it) 1996-07-31 1998-04-30 Medidom Lab Procedimento per la preparazione di reina e diacereina
IT1283771B1 (it) 1996-07-31 1998-04-30 Medidom Lab Procedimento per la preparazione di derivati della reina
JP4049406B2 (ja) * 1996-10-15 2008-02-20 正規 小菅 津液改善剤及びそれを含有する経口投与用組成物
JP4018764B2 (ja) * 1996-10-18 2007-12-05 正規 小菅 津液改善用皮膚外用剤
JPH10129556A (ja) 1996-10-28 1998-05-19 Fumiaki Mori 盗難防止自転車
FR2757397B1 (fr) * 1996-12-23 1999-03-05 Mazal Pharma Composition pharmaceutique a base de rheine ou de diacerheine a biodisponibilite amelioree
IT1297038B1 (it) 1997-12-30 1999-08-03 Medidom Lab Procedimento per la preparazione di reina e suoi diacilderivati

Also Published As

Publication number Publication date
TR200400228T4 (tr) 2004-02-23
PL356784A1 (pl) 2004-07-12
MXPA02006610A (es) 2004-09-10
DE60101309D1 (de) 2004-01-08
DK1248608T3 (da) 2004-04-05
IL150390A (en) 2007-07-24
DE60101309T2 (de) 2004-09-16
ATE254913T1 (de) 2003-12-15
CZ301129B6 (cs) 2009-11-11
CA2396111C (en) 2008-12-02
ES2210120T3 (es) 2004-07-01
BRPI0107493B1 (pt) 2019-04-16
RU2266740C2 (ru) 2005-12-27
SK286589B6 (sk) 2009-01-07
JP2003519653A (ja) 2003-06-24
WO2001051044A3 (en) 2002-03-28
EP1248608A2 (de) 2002-10-16
BR0107493A (pt) 2002-10-08
PT1248608E (pt) 2004-04-30
AR026801A1 (es) 2003-02-26
CZ20022382A3 (cs) 2002-11-13
BRPI0107493B8 (pt) 2021-05-25
AU2213201A (en) 2001-07-24
JP4912554B2 (ja) 2012-04-11
CN1187045C (zh) 2005-02-02
US20050004045A1 (en) 2005-01-06
AU776324B2 (en) 2004-09-02
US6844365B2 (en) 2005-01-18
EP1248608B1 (de) 2003-11-26
CA2396111A1 (en) 2001-07-19
SK9912002A3 (en) 2003-02-04
US20020143057A1 (en) 2002-10-03
CN1395484A (zh) 2003-02-05
WO2001051044A2 (en) 2001-07-19
PL212010B1 (pl) 2012-07-31
IL150390A0 (en) 2002-12-01

Similar Documents

Publication Publication Date Title
AU776324B2 (en) Substances for use in treating psoriasis
Perlroth et al. Oral contraceptive agents and the management of acute intermittent porphyria
NO333257B1 (no) Anvendelse av dialkylfumarater for fremstilling av medikamenter til behandling av multippel sklerose
WO1991013627A1 (en) Tripterygium wilfordii hook f extracts and components thereof for immunosuppression
US20070054886A1 (en) Ras antagonists for treating neurodegenerative disorders
Lewis et al. Dose effects of chlorpromazine on human sleep
US20040142034A1 (en) Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulators
Emmerson Regimen of indomethacin therapy in acute gouty arthritis
EP0502048A1 (de) Verwendung von kaffein bei der behandlung von herpes-simplex-virusinfektionen.
ITMI952242A1 (it) Composizione farmaceutica per il trattamento delle malattie autoimmuni
Todd et al. Suprofen: a review of its pharmacodynamic and pharmacokinetic properties, and analgesic efficacy
JPS61176524A (ja) 抗炎症組成物
Morley et al. A comparative trial of a controlled-release formulation of ketoprofen (‘Oruvail’) and a conventional capsule formulation of ketoprofen (‘Orudis’) in patients with osteoarthritis of the hip
Joubert, PH,* Kushlick, AR,** McNeill, WG,*** Sheard, ESC**** & Muller South African multricentre trial with voltaren in osteo-arthritis of the knee
CA1268125A (en) Use of a retinoid
Lam et al. Reducing meal-stimulated acid secretion versus reducing nocturnal acid secretion for healing of duodenal ulcer
Berry et al. Antrafenine, naproxen and placebo in osteoarthritis: a comparative study
CN109045054A (zh) 七叶皂苷的新用途
Howard A Double-Blind Crossover Evaluation of Ketoprofen (Orudis®) and Placebo in Rheumatoid Arthritis with Assessment of Long-Term Tolerance
Vorhaus et al. Clinical experiments with Riboflavin, inositol and calcium Pantothenate
CN114652706A (zh) 石斛酚及其组合物在制备治疗过敏性皮肤病药物中的应用
CN119587533A (zh) 一种抗氧化剂α-硫辛酸在制备改善胃炎的药物中的应用
do Espírito Santo¹ et al. Graves’ Disease and Down Syndrome: Case Report
Kaarela et al. The effect of different indomethacin formulations in young and elderly patients: a comparative controlled clinical trial
Lowenthal Malignant hypertension secondary to idiopathic arteritis of the aorta